Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Summit Therapeutics Inc. stands amongst them.

Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cell lung cancer (NSCLC), has made significant strides with its lead investigational drug, ivonescimab. The HARMONi Phase III trial for EGFR-mutated NSCLC patients demonstrated a statistically significant improvement in progression-free survival when ivonescimab was combined with platinum-based chemotherapy versus placebo. While overall survival trends were positive, they did not reach statistical significance.

Summit Therapeutics Inc. (NASDAQ:SMMT) recently received approval in China for ivonescimab as a first-line treatment for PD-L1-positive advanced NSCLC, reflecting geographic expansion. Patient enrollment is ongoing in global Phase III trials, including the newly initiated U.S. cohorts, highlighting continued momentum in clinical development.

Despite these advances, the business’s stock has faced volatility in 2025. Investor concerns have arisen from mixed trial outcomes in North America and Europe compared to stronger results in China, raising questions about broader commercial potential. Additionally, Summit Therapeutics Inc. (NASDAQ:SMMT) is navigating legal scrutiny from a securities fraud lawsuit tied to the Pinnacle Study.

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.